Genmab A/S (CPH: GMAB)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 118.96B |
| Revenue (ttm) | 19.02B |
| Net Income (ttm) | 5.54B |
| Shares Out | 63.49M |
| EPS (ttm) | 84.41 |
| PE Ratio | 22.19 |
| Forward PE | 24.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,401 |
| Open | 1,880.00 |
| Previous Close | 1,877.50 |
| Day's Range | 1,860.00 - 1,881.00 |
| 52-Week Range | 1,691.00 - 2,710.00 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About Genmab
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB... [Read more]
Financial Performance
In 2023, Genmab's revenue was 16.47 billion, an increase of 13.57% compared to the previous year's 14.51 billion. Earnings were 4.35 billion, a decrease of -20.18%.
Financial StatementsNews
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry o...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
AbbVie, Genmab receive European approval for Tepkinly in follicular lymphoma
Genmab and AbbVie receive conditional approval from the European Commission for Tepkinly as monotherapy for follicular lymphoma after two lines of therapy. Read more here.
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monot...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, t...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increa...
Genmab A/S 2024 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Genmab A/S in conjunction with their 2024 Q2 earnings call.
Genmab A/S (GMAB) Q2 2024 Earnings Call Transcript
Genmab reports 1H results
Genmab's financial results for 1H 2024 show a significant increase in revenue to DKK 9,545 million compared to DKK 7,003 million in 1H 2023.
Genmab Announces Financial Results for the First Half of 2024
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to t...
Genmab Updates 2024 Financial Guidance
Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acquisition and integrat...
Genmab stock slides 7% as BioNTech ends acasunlimab collaboration
Genmab (GMAB) stock fell 7% on news partner BioNTech (BNTX) has decided not to pursue development of their bispecific antibody therapy acasunlimab. Read more here.
Genmab Takes Full Control of Acasunlimab Development Program
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development ...
J&J wins another FDA label expansion for multiple myeloma therapy
J&J (JNJ) wins FDA nod to further expand the label for its multiple myeloma drug Darzalex Faspro developed with Genmab (GMAB) and Halozyme (HALO). Read more here.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
Company Announcement Net sales of DARZALEX ® in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, D...
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced t...
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults wi...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion ...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of th...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 05, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate...
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, p...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates p atients with previously untreated follicular lymphoma (FL) who received epcorit...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating ...